We also discovered the underlying molecular mechanism in which only the combo treatment induces expression and promotes co-occupancy of key transcription factors such as IRF7 and the co-activator β-catenin to drive transcription of genes in the type I IFN signalling pathway such as STAT1, which is critical for AML differentiation42–44. The gene discussed is IRF7; the disease is acute myeloid leukemia.